Semaglutide's STEP 1 trial (1,961 subjects, 68 weeks) demonstrated 14.9% mean weight loss
No - it's a small-molecule compound, not a peptide
The bioavailability problem This is where the oral versus injection comparison gets uncomfortable for oral advocates
Clinical trial safety data: In the Phase 2 trial, adverse events were comparable to placebo
Before enrolling, youll receive detailed information through an informed consent process so you can weigh all the pros and cons of participating first
"And certainly if they're going to be starting a GLP-1, it's always safer to have an exam prior to and shortly after starting treatment if there's any changes in the vision." For people worried about potential vision complications or wondering if a GLP-1 can cause blindness, Dr